Literature DB >> 24489562

HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Cécile Tremblay1, Isabelle Hardy2, Richard Lalonde3, Benoit Trottier4, Irina Tsarevsky5, Louis-Philippe Vézina6, Michel Roger2, Mark Wainberg7, Jean-Guy Baril8.   

Abstract

HIV-1 tropism assays play a crucial role in determining the response to CCR5 receptor antagonists. Initially, phenotypic tests were used, but limited access to these tests prompted the development of alternative strategies. Recently, genotyping tropism has been validated using a Canadian technology in clinical trials investigating the use of maraviroc in both experienced and treatment-naive patients. The present guidelines review the evidence supporting the use of genotypic assays and provide recommendations regarding tropism testing in daily clinical management.

Entities:  

Keywords:  CCR5; HIV; Maraviroc; Tropism

Year:  2013        PMID： 24489562      PMCID： PMC3905003          DOI： 10.1155/2013/982759

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN： 1712-9532            Impact factor:   2.471


  92 in total

1.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.

Authors:  C P Dorn; P E Finke; B Oates; R J Budhu; S G Mills; M MacCoss; L Malkowitz; M S Springer; B L Daugherty; S L Gould; J A DeMartino; S J Siciliano; A Carella; G Carver; K Holmes; R Danzeisen; D Hazuda; J Kessler; J Lineberger; M Miller; W A Schleif; E A Emini
Journal:  Bioorg Med Chem Lett       Date:  2001-01-22       Impact factor: 2.823

Review 2.  Emerging anti-HIV drugs.

Authors:  Erik De Clercq
Journal:  Expert Opin Emerg Drugs       Date:  2005-05       Impact factor: 4.191

3.  CCR5 interactions with the variable 3 loop of gp120.

Authors:  Kelby B Napier; Zi-xuan Wang; Stephen C Peiper; John O Trent
Journal:  J Mol Model       Date:  2006-05-24       Impact factor: 1.810

4.  The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.

Authors:  M M Santoro; D Armenia; L Fabeni; M Santoro; C Gori; F Forbici; V Svicher; A Bertoli; L Dori; M Surdo; E Balestra; G Palamara; E Girardi; G Angarano; M Andreoni; P Narciso; A Antinori; F Ceccherini-Silberstein; C F Perno
Journal:  Clin Microbiol Infect       Date:  2012-06-08       Impact factor: 8.067

5.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

Authors:  G Scarlatti; E Tresoldi; A Björndal; R Fredriksson; C Colognesi; H K Deng; M S Malnati; A Plebani; A G Siccardi; D R Littman; E M Fenyö; P Lusso
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.

Authors:  Cathia Soulié; Slim Fourati; Sidonie Lambert-Niclot; Isabelle Malet; Marc Wirden; Roland Tubiana; Marc-Antoine Valantin; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  J Antimicrob Chemother       Date:  2010-02-11       Impact factor: 5.790

7.  HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection.

Authors:  Benedikt Simon; Katharina Grabmeier-Pfistershammer; Armin Rieger; Mario Sarcletti; Brigitte Schmied; Elisabeth Puchhammer-Stöckl
Journal:  AIDS       Date:  2010-08-24       Impact factor: 4.177

8.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

9.  Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.

Authors:  Seble Kassaye; Elizabeth Johnston; Bryan McColgan; Rami Kantor; Lynn Zijenah; David Katzenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

10.  CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA.

Authors:  Chris Verhofstede; Linos Vandekerckhove; Veerle Van Eygen; Els Demecheleer; Ina Vandenbroucke; Bart Winters; Jean Plum; Dirk Vogelaers; Lieven Stuyver
Journal:  J Acquir Immune Defic Syndr       Date:  2009-02-01       Impact factor: 3.731
View more
  2 in total

1.  Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death.

Authors:  Maria Casadellà; Alessandro Cozzi-Lepri; Andrew Phillips; Marc Noguera-Julian; Markus Bickel; Dalibor Sedlacek; Kai Zilmer; Bonaventura Clotet; Jens D Lundgren; Roger Paredes
Journal:  PLoS One       Date:  2017-01-27       Impact factor: 3.240

2.  HIV-1C env and gag Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana.

Authors:  Nametso Kelentse; Sikhulile Moyo; Mompati L Mogwele; Doreen Ditshwanelo; Baitshepi Mokaleng; Natasha O Moraka; Kwana Lechiile; Tshepo B Leeme; David S Lawrence; Rosemary Musonda; Ishmael Kasvosve; Thomas S Harrison; Joseph N Jarvis; Simani Gaseitsiwe
Journal:  Viruses       Date:  2020-12-07       Impact factor: 5.048
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.